caa a22 4500 605490333 CHVBK 20210128100504.0 cr unu---uuuuu 210128e20150201xx s 000 0 eng 10.1007/s10147-014-0757-4 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0757-4 Cancer registries in Japan: National Clinical Database and site-specific cancer registries [Elektronische Daten] [Takayuki Anazawa, Hiroaki Miyata, Mitsukazu Gotoh] Abstract : The cancer registry is an essential part of any rational program of evidence-based cancer control. The cancer control program is required to strategize in a systematic and impartial manner and efficiently utilize limited resources. In Japan, the National Clinical Database (NCD) was launched in 2010. It is a nationwide prospective registry linked to various types of board certification systems regarding surgery. The NCD is a nationally validated database using web-based data collection software; it is risk adjusted and outcome based to improve the quality of surgical care. The NCD generalizes site-specific cancer registries by taking advantage of their excellent organizing ability. Some site-specific cancer registries, including pancreatic, breast, and liver cancer registries have already been combined with the NCD. Cooperation between the NCD and site-specific cancer registries can establish a valuable platform to develop a cancer care plan in Japan. Furthermore, the prognosis information of cancer patients arranged using population-based and hospital-based cancer registries can help in efficient data accumulation on the NCD. International collaboration between Japan and the USA has recently started and is expected to provide global benchmarking and to allow a valuable comparison of cancer treatment practices between countries using nationwide cancer registries in the future. Clinical research and evidence-based policy recommendation based on accurate data from the nationwide database may positively impact the public. Japan Society of Clinical Oncology, 2014 Cancer registry nationallicence Nationwide database nationallicence Risk factor nationallicence Risk model nationallicence Anazawa Takayuki Department of Regenerative Surgery, Fukushima Medical University, 1 Hikarigaoka, 960-1295, Fukushima, Japan aut Miyata Hiroaki Department of Healthcare Quality Assessment, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan aut Gotoh Mitsukazu Department of Regenerative Surgery, Fukushima Medical University, 1 Hikarigaoka, 960-1295, Fukushima, Japan aut International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 5-10 1341-9625 20:1<5 2015 20 10147 https://doi.org/10.1007/s10147-014-0757-4 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 review-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0757-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Anazawa Takayuki Department of Regenerative Surgery, Fukushima Medical University, 1 Hikarigaoka, 960-1295, Fukushima, Japan aut NATIONALLICENCE 700 1- Miyata Hiroaki Department of Healthcare Quality Assessment, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan aut NATIONALLICENCE 700 1- Gotoh Mitsukazu Department of Regenerative Surgery, Fukushima Medical University, 1 Hikarigaoka, 960-1295, Fukushima, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 5-10 1341-9625 20:1<5 2015 20 10147